Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study.
Monestier S, Dalle S, Mortier L, Dutriaux C, Dalac-Rat S, Meyer N, Leccia MT, Mansard S, Montaudié H, Saiag P, Combemale P, Guillot B, Skowron F, Duval Modeste AB, Bénéton N, Hainaut E, Robert C, Arnault JP, Le Corre Y, Jouary T, Ameur N, Varey E, Khammari A, Dréno B; RIC-Mel network. Monestier S, et al. Among authors: jouary t. Int J Cancer. 2021 Jun 1;148(11):2789-2798. doi: 10.1002/ijc.33467. Epub 2021 Feb 19. Int J Cancer. 2021. PMID: 33428772 Clinical Trial.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. Among authors: jouary t. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial.
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James MG, Strauss UP, Prendergast S, Gore ME. Eisen T, et al. Among authors: jouary t. Br J Cancer. 2011 Jul 26;105(3):353-9. doi: 10.1038/bjc.2011.257. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750549 Free PMC article. Clinical Trial.
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ, Jouary T, Dréno B, Asselineau J, Gutzmer R, Hauschild A, Leccia MT, Landthaler M, Garbe C, Sassolas B, Herbst RA, Guillot B, Chene G, Pehamberger H. Grob JJ, et al. Among authors: jouary t. Eur J Cancer. 2013 Jan;49(1):166-74. doi: 10.1016/j.ejca.2012.07.018. Epub 2012 Sep 10. Eur J Cancer. 2013. PMID: 22975216 Clinical Trial.
Metastatic melanoma with leukaemia-like evolution.
Bertolotti A, Conte H, Amazan E, Dutriaux C, Ezzedine K, Parrens M, Vergier B, Taieb A, Jouary T. Bertolotti A, et al. Among authors: jouary t. Acta Derm Venereol. 2013 Nov;93(6):729-30. doi: 10.2340/00015555-1581. Acta Derm Venereol. 2013. PMID: 23529281 Free article. No abstract available.
Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, Mortier L, Bedane C, Girard C, Thellier S, Jouary T, Grob JJ, Richard MA, Templier C, Sakji L, Guillot B, Paul C, Meyer N. Konstantinou MP, et al. Among authors: jouary t. Acta Derm Venereol. 2014 Jan;94(1):45-9. doi: 10.2340/00015555-1654. Acta Derm Venereol. 2014. PMID: 23824275 Free article.
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. McArthur GA, et al. Among authors: jouary t. Lancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7. Lancet Oncol. 2014. PMID: 24508103 Free PMC article. Clinical Trial.
[Systemic treatment of melanoma brain metastases].
Le Rhun É, Mateus C, Mortier L, Dhermain F, Guillot B, Grob JJ, Lebbe C, Thomas M, Jouary T, Leccia MT, Robert C. Le Rhun É, et al. Among authors: jouary t. Cancer Radiother. 2015 Feb;19(1):48-54. doi: 10.1016/j.canrad.2014.11.010. Epub 2015 Feb 2. Cancer Radiother. 2015. PMID: 25656856 Review. French.
Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma.
Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Dompmartin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, Mateus C. Jouary T, et al. Acta Derm Venereol. 2015 Sep;95(7):835-40. doi: 10.2340/00015555-2099. Acta Derm Venereol. 2015. PMID: 25784178 Free article.
131 results